Lixte Biotechnology Holdings Inc reported that it received a notice from Nasdaq on August 19, 2024, for not meeting the minimum stockholders equity requirement of $2.5 million, and has until February 18, 2025, to regain compliance, with an appeal process initiated to avoid delisting.